
14.	Stock-Based Compensation

We currently have two stock-based compensation plans, the Amended and Restated Employee Stock Purchase Plan (the “ESPP”) and the Second Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”). As of December 31, 2017, 9,092 shares remained available for issuance under the ESPP and 1,082,668 shares remained available for issuance under the 2014 Plan.

Exercises and vestings under our stock-based compensation plans resulted in $0 in income tax-related charges to additional paid-in capital during the year ended December 31, 2017, with $(82,000) in such charges for the year ended December 31, 2016.

Restricted Stock and Restricted Stock Unit Awards

During the year ended December 31, 2017 and 2016, we granted 102,000 and 321,068 shares of restricted stock (net of any forfeitures), respectively, with aggregate grant date fair values of $0.3 million and $1.0 million, respectively. We incurred expenses of $0.6 million and $0.6 million during the year ended December 31, 2017 and 2016, respectively, related to restricted stock and restricted stock unit awards. When we grant restricted stock, we defer the grant date value of the restricted stock and amortize that value (net of the value of anticipated forfeitures) as compensation expense with an offsetting entry to the additional paid-in capital component of our consolidated shareholders’ equity. Our restricted stock awards typically vest over a range of 12 to 60 months (or other term as specified in the grant) and are amortized to salaries and benefits expense ratably over applicable vesting periods. As of December 31, 2017, our unamortized deferred compensation costs associated with non-vested restricted stock awards were $0.1 million with a weighted-average remaining amortization period of 0.4 years.

Stock Options

Our 2014 Plan provides that we may grant options on or shares of our common stock (and other types of equity awards) to members of our Board of Directors, employees, consultants and advisors. The exercise price per share of the options may be less than, equal to, or greater than the market price on the date the option is granted. The option period may not exceed 5 years from the date of grant. The vesting requirements for options could range from 0 to 5 years. We had expense of $0.9 million and $0.8 million related to stock option-related compensation costs during the years ended December 31, 2017 and 2016, respectively. When applicable, we recognize stock option-related compensation expense for any awards with graded vesting on a straight-line basis over the vesting period for the entire award. Information related to options outstanding is as follows:



	December 31, 2017
	Number of Shares		Weighted- Average Exercise Price		Weighted- Average of Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2016	1,411,667		$	3.09
Issued	1,215,000		$	2.98
Exercised	—		$	—
Cancelled/Forfeited	(7,333	)	$	3.04
Outstanding at December 31, 2017	2,619,334		$	3.04	3.3	$	17,312
Exercisable at December 31, 2017	794,871		$	2.92	2.1	$	17,312

We had $0.9 million and $0.7 million of unamortized deferred compensation costs associated with non-vested stock options as of December 31, 2017 and 2016, respectively.